Table 3.

Selection percentages for each dose under the proposed method for various design specifications. The maximum sample size for each simulated trial was N = 48 patients. The OBD in each scenario is indicated in bold-type.

Scenario 1	True (toxicity, efficacy) probability
	(0.01, 0.30)	(0.05, 0.50)	(0.10, 0.60)	(0.15, 0.40)	(0.20, 0.25)
ψ = 0; nR = 12	0.069	0.321	0.515	0.078	0.017
ψ = 0; nR = 24	0.049	0.327	0.567	0.053	0.004
ψ = 0; nR = 36	0.042	0.305	0.593	0.058	0.002
ψ = 0; nR = 48	0.062	0.285	0.587	0.060	0.006
ψ = −2; nR = 12	0.082	0.315	0.513	0.077	0.013
ψ = 2; nR = 12	0.063	0.303	0.512	0.107	0.015
Scenario 2	(0.02, 0.38)	(0.06, 0.50)	(0.12, 0.40)	(0.30, 0.30)	(0.40, 0.25)
ψ = 0; nR = 12	0.253	0.481	0.211	0.050	0.005
ψ = 0; nR = 24	0.241	0.538	0.182	0.034	0.005
ψ = 0; nR = 36	0.255	0.542	0.180	0.021	0.002
ψ = 0; nR = 48	0.265	0.537	0.158	0.035	0.005
ψ = −2; nR = 12	0.227	0.512	0.205	0.051	0.005
ψ = 2; nR = 12	0.250	0.468	0.206	0.064	0.012
Scenario 3	(0.03, 0.25)	(0.09, 0.35)	(0.16, 0.48)	(0.28, 0.65)	(0.42, 0.52)
ψ = 0; nR = 12	0.098	0.124	0.278	0.474	0.026
ψ = 0; nR = 24	0.061	0.095	0.271	0.540	0.033
ψ = 0; nR = 36	0.048	0.082	0.266	0.561	0.043
ψ = 0; nR = 48	0.061	0.061	0.215	0.539	0.124
ψ = −2; nR = 12	0.078	0.130	0.297	0.455	0.040
ψ = 2; nR = 12	0.073	0.118	0.256	0.526	0.027
Scenario 4	(0.02, 0.68)	(0.05, 0.56)	(0.07, 0.49)	(0.09, 0.40)	(0.11, 0.33)
ψ = 0; nR = 12	0.627	0.211	0.115	0.034	0.013
ψ = 0; nR = 24	0.672	0.230	0.084	0.009	0.005
ψ = 0; nR = 36	0.713	0.206	0.069	0.011	0.001
ψ = 0; nR = 48	0.748	0.183	0.055	0.011	0.003
ψ = −2; nR = 12	0.644	0.214	0.094	0.031	0.017
ψ = 2; nR = 12	0.622	0.216	0.099	0.045	0.018